FDA Approves Abbott's PVL Occluder and Validates Paradigm Study
What happened
The U.S. Food and Drug Administration granted approval to Abbott for the Amplatzer Paraclose PVL Occluder, a device designed to treat paravalvular leak (PVL). This device is the only transcatheter option approved in the U.S. specifically for PVL. Additionally, the FDA approved a PARADIGM study based on information from the Cleveland Clinic.
From dicardiology.com
Why it matters
The approval addresses a significant treatment gap for patients suffering from PVL, a condition that can result from heart valve replacements. The Amplatzer Paraclose device offers a minimally invasive treatment option for this condition.
From dicardiology.com
Who's involved
- FDARegulatory agency that granted approval for the medical device and the study data.
- AbbottManufacturer of the Amplatzer Paraclose PVL Occluder, which received FDA approval.
- ParadigmCompany whose study data was approved by the FDA.
- Cleveland ClinicAcademic medical center whose data was used in the approved PARADIGM study.
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- AbbottSpeculative
Abbott might see increased sales and revenue due to the unique market position of the approved device.
- ParadigmSpeculative
Paradigm could see a boost in reputation and investment interest following the FDA validation of its study data.
- Cleveland ClinicSpeculative
The Cleveland Clinic might see increased demand for its specialized medical services and related revenue.
Keep exploring
The entities involved
- FDA
-
Abbott
city in Hill County, Texas, United States
-
Paradigm
Japanese book publisher
Nothing else this week.
Related events
- FDA approval expands patient access to therapies for ACCORD.
- A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.
- FDA provided guidance for HCW Biologics' IND application.
- An AI software company based in Baltimore is seeking FDA clearance and planning a clinic pilot in New Orleans.
- FDA, LabCorp, and Charles River Laboratories formed a collaboration to evaluate the potential for medicine abuse.